* Bionano Genomics Inc BNGO.OQ BNGO.O is expected
to show a
rise in quarterly revenue when it reports results on November
3.
* The San Diego California-based company is expected to
report a
46.0% increase in revenue to $6.794 million from $4.66 million a
year ago, according to the mean estimate from 3 analysts, based
on Refinitiv data.
* Refinitiv's mean analyst estimate for Bionano Genomics
Inc is
for a loss of 11 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 3 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Bionano
Genomics
Inc is $12, above its last closing price of $2.38.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2022 -0.10 -0.09 -0.11 Missed -20.4
Mar. 31 2022 -0.09 -0.07 -0.11 Missed -46.7
Dec. 31 2021 -0.06 -0.06 -0.08 Missed -23.6
Sep. 30 2021 -0.06 -0.06 -0.07 Missed -30.6
Jun. -0.05 -0.05 -0.06 Missed -32.6
30 2021
Mar. 31 2021 -0.05 -0.04 -0.04 Met 11.1
Dec. 31 2020 -0.05 -0.05 -0.05 Met 4.8
Sep. 30 2020 -0.05 -0.05 -0.08 Missed -52.4
This summary was machine generated November 1 at 22:38 GMT. All
figures in US dollars unless otherwise stated